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ISSObjective: To assess morbidity and mortality in HIV-exposed uninfected (HEU) chil-
dren to help guiding appropriate clinical care and effective preventive interventions.
Design: This is a longitudinal study comparing two cohorts of children; one born to
HIV-infected women and the other born to HIV-uninfected women.
Methods: We have analyzed prospectively obtained information on nutritional status,
morbidity and mortality from 966 HEU and 909 HIV-unexposed infants followed up
until their first 18 months of life at a referral health facility in southern Mozambique.
Determinants for adverse health outcomes in HEU children were also assessed using
multivariate logistic regression.
Results: Increased incidence of hospital admissions (P¼0.0015), shorter survival in the
first 18 months of life (P¼0.0510) and moderate and severe malnutrition (P¼0.0006
and 0.0014, respectively) were observed among HEU children compared with HIV-
unexposed children. Incidence of outpatient attendance in HEU children was associ-
ated with being men, older age and the mother being on antiretroviral treatment. Among
HEU children, those who were never breastfed, or who were weaned or were partially
breastfed, had an increased incidence of hospital admissions compared with children
who were exclusively breastfed.
Conclusion: Maternal HIV infection has important health consequences in non-HIV-
infected children. As the prevalence ofHIV-infected pregnantwomen is maintainedand the
proportion of HIV-infected children declines because of the scale-up of antiretroviral
treatment during pregnancy and breastfeeding, more focus should be given to the health
needs of HEU children to ensure that the post-2015 sustainable development goals are met.
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HIV-infected pregnant and breastfeeding women, is
expected to further reduce the incidence of new HIV
infections and potentially eliminate mother-to-child
transmission (MTCT) of HIV [2]. Although current
programatic efforts are focused in reducing new HIV
pediatric infections, the number of children who are HIV-
exposed but uninfected is increasing proportionately.
Every year, over 1 million infants are born to HIV-infected
women worldwide, the majority of them in low-income
countries, and most of them will not become infected [3].
HIV-exposed uninfected (HEU) children are increasingly
recognized as a group with specific health needs. Direct
or indirect HIV exposure in utero, intra partum or during
breastfeeding may confer risks even in the absence of
infection. Several studies have described increased
mortality and enhanced risk of poor health and growth
outcomes in HEU compared with HIV-unexposed
children [4–11]. However, the nature of the vulnerability
of the HEU children is not entirely clear. In addition to
some immunological abnormalities that have been
observed in HEU children, exposure to antiretroviral
drugs both in utero and the neonatal period, feeding
practices as well as a particular family environment, might
all contribute to poor health outcomes [12].
Mozambique is one of the countries with the highest HIV
prevalence and incidence in the world [13]. In some areas,
up to 40% of pregnant women attending the antenatal
care (ANC) clinics are HIV-infected [14,15]. After more
than 10 years since the rollout of antiretrovirals in the
country, a 57% reduction in new HIV infections among
children has been reported between 2009 and 2013 [16].
However, there are very limited data on health outcomes
and survival of HEU children. A better understanding of
the impact of maternal HIV infection on the health
outcomes of exposed children is needed in low-income
settings, where malnutrition and comorbidities are
frequent and health monitoring resources are limited.
This study compares the survival and health outcomes
between two cohorts of HIV-exposed and HIV-
unexposed children and identifies determinants for
morbidity among the HEU children.Methods
Study design
The current study compares prospectively obtained data
on nutritional status, morbidity and mortality during the
first 18 months of life, between two cohorts of children:
one cohort born to HIV-infected women and the other
born to HIV-uninfected women.
Study area and population
The study was conducted at the Manhiça District
Hospital (MDH), located in a semirural area of theMaputo Province in southern Mozambique. Since 1996,
the Centro de Investigação em Saúde de Manhiça has
conducted continuous demographic surveillance cover-
ing a population of approximately 95 000 inhabitants in
an area of 500 km2 [17]. Passive morbidity surveillance
was established in parallel at the MDH and peripheral
health posts in the area, whereby all pediatric hospital
admissions and outpatient attendances are registered
onto standardized questionnaires following standard
procedures.
The average HIV prevalence figure in 2015 in
Mozambique was 11% [18]. However, a community-
based survey undertaken in the Manhiça area among
adults in 2012 reported nearly 40% of HIV prevalence.
The contemporaneous HIV seroprevalence among
pregnant women attending the ANC clinics was 30%
[15]. A prevalence of 9% of MTCT at first month of age
and of 25% at the end of the first year of life has also been
reported in the area [19,20]. Before 2013, PMTCTrelied
on antiretroviral prophylaxis, which consisted in ante-
partum monotherapy with zidovudine (ZDV), a single-
dose nevirapine (NVP) at the onset of labor, and
ZDVþ lamivudine (3TC) at delivery and for 7 days post
partum. Daily ZDVor NVP was recommended for infant
prophylaxis during breastfeeding. National guidelines
recommended ART to HIV-infected pregnant women
for their own health if the CD4þ T-cell count was less
than 350 cells/ml and/or they were in 3–4 HIV/AIDS
WHO clinical stage. The recommended first-line regi-
men consisted in the dual nucleoside analog reverse-
transcriptase Inhibitors backbone [3TC and either ZDV
or stavudine (d4T)] and an nonnucleoside analog reverse-
transcriptase Inhibitors [either NVP or efavirenz (EFV)]
[21]. In 2013, Mozambique adopted ‘Option Bþ’,
consisting in the initiation of lifelong ARTwith tenofovir
(TDF)þ 3TCþEFV in all HIV-positive pregnant and
lactating women regardless of their immune status and
clinical stage [22]. According to this recommendation,
both breastfed and formula-fed infants should receive
once-daily NVP from birth to 6 weeks of age. Cotri-
moxazol prophylaxis (CTXp) is also recommended from
4 weeks until 2 months after weaning, whereas




A total of 909 children born between February 2010 and
October 2012 to HIV-uninfected women participating
in a trial comparing mefloquine with sulphadoxine–
pyrimethamine as intermittent preventive treatment of
malaria in pregnancy were included in this study. Results
from the trial showed no differences in mortality,
morbidity and nutritional status between infants born
to women allocated to either study group [23,24]. As part
of clinical trial procedures, at delivery, newborns were
given a study number to be uniquely identified. Mothers
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1 month of age, or coinciding with the first expanded
program on immunization visit, and then at 9 and
12 months of age for study scheduled visits. Both at
delivery and at study visits, weight and length were
recorded onto standardized questionnaires.
HIV-exposed uninfected children
There were 966 children included in this study who were
born to HIV-infected women, followed up at the High-
Risk Pediatric Outpatient Clinic (HRPOC) of the MDH
and born between January 2010 and December 2013.
This study cohort included the children until they
became HIV infected, died or ended the follow-up at
18 months of age.
As per national guidelines, children born to HIV-infected
women were recommended to attend monthly visits at
the HRPOC from the first month of life. In these visits,
feeding habits and anthropometric and clinical charac-
teristics were assessed. Informed consent was obtained,
and data were collected prospectively onto standardized
questionnaires in each of the subsequent visits to the
HRPOC. Data from delivery, newborn baseline charac-
teristics and uptake of PMTCT interventions during
pregnancy were extracted retrospectively from the infant’s
Health Card. An HIV-DNA PCR test between 4 and
6 weeks of age was performed, with a confirmatory test
on a new sample in those infants who test positive in the
PCR. If the PCR test was negative, an HIV-antibody
rapid test was performed at 9 months of age, and viral
testing was carried out in those children with a positive
serological test. The definitive diagnosis of HIV infection
through HIV-antibody testing was determined at
18 months of age or when the risk of HIV exposure
through breastfeeding ended. Infected infants were
referred to the Pediatric HIV Outpatient Clinic for
follow-up and ART initiation.
In both cohorts, information on hospital admissions and
outpatient attendances during the first 18 months of
life was obtained from the MDH passive morbidity
surveillance system. Data on mortality were extracted
from the demographic surveillance system in place.
Laboratory methods
HIV status was assessed from dried blood spot on filter
paper using the Amplicor HIV-1 DNA-PCR kit (Roche
Diagnostics, Branchburg, New Jersey, USA). Determine
HIV-1/2 Rapid Test (Abbott Laboratories, Chicago,
Illinois, USA) and Uni-Gold Rapid Test (Trinity Biotech,
Dublin, County Wicklow, Ireland) were used for HIV
serological testing on whole blood collected by finger
prick. Hemoglobin was determined using mobile devices
in capillary blood samples [HemoCue (www.eurotrol.
com) and Hemocontrol (www.ekfdiagnostics.com)].
Thick and thin blood films were stained and read forPlasmodium species detection according to standard,
quality-controlled procedures [25].
Data management, statistical methods and
definitions
Data were double-entered using the OpenClinica
Enterprise software for clinical data management (www.
openclinica.com).
Low birth weight (LBW) was defined as weight less than
2500 g at birth and preterm as a birth less than 37 weeks of
gestation. Gestational age was assessed by the Ballard’s
score at delivery. Transformation of child anthropometric
data to z-scores was performed using the least mean
squares method and the reference data available from the
2000 Centers for Disease Control and Prevention growth
reference in the United States [26,27]. Moderate
malnutrition was defined as less than 2 SD for either
weight-for-age, height-for-age or weight-for-height
z-scores, and severe malnutrition as any of the previous
z-scores under 3 SD [28]. Causes of hospital admission
were classified according to the international classification
of disease (ICD-10) coding system.
Minimum community-based incidence rates for the
morbidity outcomes (outpatient attendances, hospital
admissions and moderate/severe malnutrition) were
calculated as the number of cases in children resident
in the study area divided by the total children-years at risk
(CYARs). CYARs were estimated from the demographic
surveillance system databases. Children did not contrib-
ute to the numerator or denominator in the following
situations: for a period of 15 days after each hospital
admission, when they were outside the study area, after
seroconversion (only in the HEU group) or after death.
Cox proportional hazard models were used to assess the
differences in mortality between the different age groups.
Negative binomial regression models with random
intercept were estimated to assess the association of
HIV-exposure and other potential risk factors with the
incidence of the studied outcomes. All the variables (sex,
age, birth weight, type of delivery, location of delivery,
gestational age, mother on CTXp, breastfeeding,
maternal ART, child PMTCT and child CTXp) were
included in the multivariate models to assess their adjusted
associations with the incidence of outpatient attendances
and hospital admissions among HEU children as they
have all have been described in literature as potential
confounders. Cox regression with left truncation (or
delayed entry) was used for the evaluation of the
associations with time to death.
The statistical software for analysis was STATA 14.1 (Stata
Corp., College Station, Texas, USA).
Ethics statement and participants’ safety
Protocols from both HEU and HIV-unexposed cohorts
were reviewed and approved by the Ethics Committees
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Table 1. Baseline characteristics of HIV-exposed and HIV-unexposed newborns at birth.
Characteristics at birth
HIV-exposed HIV-nonexposed
P valueN n (%) N n (%)
Sex (males) 966 508 (53) 909 460 (51) 0.3905a
Birth weight (median, IQRb) 509 3000 (500) 906 3100 (500) 0.2420c
LBWd (<2500 g) 509 43 (8) 906 68 (8) 0.5269a
Gestational age (median, IQRb) 395 39 (3) 738 38 (3) 0.8713c
Preterm (<37 weeks) 395 74 (19) 738 103 (14) 0.0348a
Delivery location
Maternity 513 468 (91) 756 682 (90) 0.5420a
Outside maternity 513 45 (9) 756 74 (10)
Type of delivery
Vaginal 510 479 (94) 754 707 (94) 0.9105a




dLow birth weight.from the Hospital Clinic of Barcelona (Spain) and local
regulatory authorities and National Ethics Review
Committee from Mozambique. The HIV-unexposed
children trial was conducted under the provisions of the
Declaration of Helsinki and in accordance with Good
Clinical Practices guidelines set up by the WHO and by
the International Conference on Harmonization.Results
Baseline characteristics of study children at birth
A total of 966 HEU and 909 HIV-unexposed children
were followed up for their first 18 months of life. There
were 53 (508/966) and 51% (460/909) of men among
HEU and HIV-unexposed children, respectively. There
was no statistical significant difference in mean birth
weight between HEU children [3000 g (interquartile
range (IQR): 500)] and HIV-unexposed children [3100 g
(IQR: 500); P¼ 0.2420]. The prevalence of LBW was
8% in both groups. The proportion of preterm newborns
was significantly higher in HEU children (19%, 74/395)
compared with HIV-unexposed children (14%, 103/738;
P¼ 0.0348). The proportion of institutional deliveries
was similar in both groups (91%, 468/513 in HEU
children and 90%, 682/756 in HIV-unexposed children,
respectively) with no difference either in the frequency of
cesarean section by cohort, which was 6% in both groups
(Table 1).
Mortality, morbidity and malnutrition among
study children
A significantly lower incidence of outpatient attendances
during the first 18 months of life was observed among
HEU children compared with HIV-unexposed children
[incidence rate ratio (IRR)¼ 0.77, 95% confidence
interval (CI): (0.71, 0.83); P< 0.0001]. In contrast,
hospital admissions [IRR¼ 1.45, 95% CI: (1.15, 1.83);
P¼ 0.0015] and episodes of moderate or severemalnutrition [IRR¼ 2.14, 95% CI: (1.39, 3.30);
P¼ 0.0006 and IRR¼ 2.62, 95% CI: (1.45, 4.75);
P¼ 0.0014, respectively] were more frequent among
HEU children. A trend toward increased mortality was
observed in the HEU cohort with 2.20 deaths per 100
children-year at risk compared with 1.16 deaths per 100
children-year at risk in the HIV-unexposed cohort
[hazard ratio¼ 1.87, 95% CI: (1.00, 3.52); P¼ 0.0510]
(Table 2). In both HEU and HIV-unexposed cohorts,
mortality was higher in infants less than 6 months of age
than in older children. Among HEU children, mortality
rate was 2.67 per 100 CYARs [95% CI: (0.67, 10.66)]
in neonates and 4.94 [95% CI: (3.07, 7.94)] in the
1–6-month age group, whereas among HIV-unexposed
children, mortality rate in neonates was 5.28 [95% CI:
(1.98, 14.07)] and 1.67 [95% CI: (0.75, 3.72)] in children
between 1 and 6 months of age (Table 3).
Cause-specific hospital admissions are presented in
Supplementary Table 1, http://links.lww.com/QAD/
B86. Higher incidences of diarrhea and moderate or
severe malnutrition were observed among theHEUcohort
compared with the HIV-unexposed one [IRR¼ 2.10,
95% CI: (1.17, 3.63); P¼ 0.0128; IRR¼ 2.14, 95% CI:
(1.39, 3.30); P¼ 0.0006 and IRR¼ 2.62, 95% CI: (1.45,
4.75); P¼ 0.0014, respectively].
Risk factors for outpatient attendances and
hospital admissions in HIV-exposed uninfected
children
Results from the univariate and multivariate analyses for
outpatient attendances are presented in Table 4. In the
multivariate analysis, female children had lower incidence
of outpatient attendances [IRR¼ 0.82, 95% CI: (0.67,
0.99); P¼ 0.0386] compared with men, whereas children
whose mothers were on ART during pregnancy had
higher incidence of this outcome [IRR¼ 1.33, 95% CI:
(1.01, 1.75); P¼ 0.0428] compared with children whose
mothers were not on ART. Incidence of outpatient
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Table 2. Incidence of outpatient visits, hospital admissions, mortality and malnutrition in HIV-exposed uninfected and unexposed children in
first 18 months of life.
Incidences
HIV-exposed uninfected, N¼966 HIV-unexposed, N¼909
Incidence rate
ratio 95% CI P valueCases CYARa
Incidence
rate (per
100 CYARs) 95% CI Cases PYAR
Incidence
rate (per
100 CYARs) 95% CI
Outpatient
visits
3063 1233.28 248.36 (239.72,
257.32)
4157 1287.46 322.88 (313.22, 332.85) 0.77 (0.71, 0.83) <0.0001
Hospital
admissions
207 1233.68 16.78 (14.64, 19.23) 152 1292.70 11.76 (10.03, 13.78) 1.45 (1.15, 1.83) 0.0015
Mortality 27 1226.11 2.20 (1.51, 3.21) 15 1288.41 1.16 (0.70, 1.93) 1.87b (1.00, 3.52) 0.0510
Malnutrition
Moderatec 77 1238.88 6.22 (4.97, 7.77) 39 1297.26 3.01 (2.20, 4.11) 2.14 (1.39, 3.30) 0.0006
Severed 44 1240.04 3.55 (2.64, 4.77) 18 1298.12 1.39 (0.87, 2.20) 2.62 (1.45, 4.75) 0.0014
95% CI, 95% confidence interval.
aChildren-years at risk.
bHazard ratio.
cWeight-for-age (WAZ), length-for-age (LAZ) or weight-for-length (WHZ) z-scores under 2 SD.
dWAZ, LAZ or WHZ under 3 SD.attendances increased with age from 6 to 18 months
(P¼ 0.0001).
Results from the univariate and multivariate analyses for
hospital admissions are shown in Table 5. In the
multivariate analysis, the incidence of hospital admissions
decreased in older age groups, with children in the 12 to
less than 18-month age group having the lowest IRR
compared with those in the 0 to less than 1-month age
group [IRR¼ 0.13, 95% CI: (0.03, 0.64); P¼ 0.0517].
Children who were not exclusively breastfed, those who
had been weaned and children who were never breastfed
showed an increased incidence of hospital admissions
compared with children who were exclusively breastfed
[IRR¼ 2.21, 95% CI: (0.70, 6.99); IRR¼ 6.74, 95% CI:
(1.87, 24.31) and IRR¼ 2.63, 95% CI: (0.92, 7.52);
P¼ 0.0177].Discussion
There are very limited data on health outcomes and
survival in HEU children in Mozambique, one of the
countries with the highest HIV prevalence of the world.Table 3. Incidence of mortality by age group in HIV-exposed uninfected
Age
HIV-exposed uninfected
Mortality ratea (95% CI) HRb (95% CI) P
0 to <1 month 2.67 (0.67, 10.66) 1 0
1 to <6 months 4.94 (3.07, 7.94) 1.92 (0.43, 8.51)
6 to <12 months 1.22 (0.51, 2.93) 0.55 (0.11, 2.82)
12 to <18 months 0.76 (0.24, 2.34) 0.47 (0.08, 2.62)
Total 2.20 (1.51, 3.21) –
95% CI, 95% confidence interval.
aPer 100 children-years at risk.
bHazard ratio.
cCox proportional hazard models.A previously conducted study in the same area of smaller
sample size also compared morbidity and mortality
between HEU children and HIV-unexposed children.
However, this study was performed only 4 years after
intitiation of ART rollout in the country, and it did not
evaluate health determinants among HEU children [19].
The findings of the current study show that HEU
children are more likely to be undernourished, be
admitted to hospital and die within the first 18 months of
life compared with HIV-unexposed children. All of this
shows that maternal HIV infection continues to have
important adverse consequences on children’s health even
if the infection is prevented in the children.
In our study, mortality rate in HEU children almost
doubled that of HIV-unexposed children. Cohort studies
from other sub-Saharan countries have shown that,
before the availability of ART, HEU children had a higher
mortality risk than HIV-unexposed children [4,6,29].
However, reports on mortality in HEU and HIV-
unexposed children in the ARTera are scarce, and results
are heterogeneous [19,30–33]. Mortality rate in HEU
children in this study (2.2 deaths per 100 live births per
year at risk) was lower than that reported from other
countries in sub-Saharan Africa in the ART era, thoughand HIV-unexposed children in first 18 months of life.
HIV-unexposed
valuec Mortality ratea (95% CI) HRb (95% CI) P value
.0155 5.28 (1.98, 14.07) 1 0.0302
1.67 (0.75, 3.72) 0.25 (0.07, 0.94)
0.92 (0.35, 2.46) 0.12 (0.03, 0.57)
0.24 (0.03, 1.69) 0.04 (0.00, 0.51)
– 1.16 (0.70, 1.93) – –
CE: Swati; AIDS-D-16-01137; Total nos of Pages: 9;
AIDS-D-16-01137
6 AIDS 2017, Vol 00 No 00
Table 4. Risk factors for outpatient visits in HIV-exposed uninfected children.
Variable n Categories









Sex 684 Male 1 0.0122 1 0.0386
Female 0.82 (0.71, 0.96) 0.82 (0.67, 0.99)
Age 909 0 to <1 month 1 <0.0001 1 0.0001
1 to <6 months 1.07 (0.76, 1.51) 0.96 (0.54, 1.70)
6 to <12 months 1.61 (1.16, 2.23) 1.60 (0.89, 2.86)
12 to <18 months 1.54 (1.11, 2.14) 1.40 (0.77, 2.52)
Birth weight 494 2500 g 1 (0.89, 1.57) 0.2404 1 0.4885
<2500 g 1.18 1.13 (0.79, 1.72)
Type of delivery 495 Vaginal 1 (0.86, 1.67) 0.2861 1 0.1263
Cesarean 1.20 1.35 (0.92, 1.98)
Location of delivery 497 Maternity 1 0.0106 1 0.6494
Home 0.57 (0.39, 0.82) 0.80 (0.50, 1.28)
Other 0.85 (0.37, 1.92) 0.00 –
Gestational age (weeks) 384 37 weeks 1 0.7255 1 0.5085
<37 weeks 0.96 (0.76, 1.21) 0.91 (0.70, 1.19)
Mother on CTXpb 474 No 1 0.4436 1 0.2340
Yes 0.94 (0.79, 1.11) 0.89 (0.73, 1.08)
Breastfeeding 684 Exclusive 1 0.0038 1 0.2446
Partial 1.17 (0.95, 1.43) 0.82 (0.61, 1.09)
Weaned 1.38 (1.09, 1.74) 0.88 (0.62, 1.24)
Never did 1.46 (1.15, 1.84) 1.01 (0.74, 1.38)
Maternal ARTc 684 No 1 – 0.0803 1 0.0428
Yes 1.23 (0.98, 1.54) 1.33 (1.01, 1.75)
Child PMTCTd 684 No 1 0.0081 1 0.9348
Yes 1.24 (1.06, 1.44) 1.01 (0.74, 1.38)
Child CTXpb 684 No 1 0.0042 1 0.1423




dPrevention of mother-to-child transmission of HIV.comparable with the rate previously observed in this
setting (2.5 deaths per 100 live births per year at risk)
[19,34]. Importantly, the mortality rate observed in HEU
children may be underestimated as only children who
were passively followed up at the HRPOC were included
in the analysis, and therefore those who may have died
before follow-up intitiation or not engaged in healthcare
were not part of it. This is supported by the the mortality
rate distribution observed by age group, whereby in the
first month of life, death rate in HIV-unexposed children
was twice as high as that in HEU children, whereas this
was the opposite in the other age group. This may be
explained by neonatal deaths occurring before initiation
of follow-up at the HRPOC among HEU children not
being captured. Contrarily, estimates in HIV-unexposed
children could be regarded as minimum estimates, as they
refer to children who were enrolled in a clinical trial in
which healthcare and follow-up might have been better
than those in the general population.
The risk of all-cause hospital admissions in the first
18 months of life was significantly higher in HEU
children compared with HIV-unexposed children, which
is consistent with the findings of previous studies
conducted in the context of available antiretrovirals for
PMTCT [7,9,32]. Diarrhea (loose or watery stools morethan three times in 1 day according to ICD-10 coding
system) was more frequent among HEU compared with
HIV-unexposed children. There is no conclusive
evidence as to whether the risk of diarrhea is different
in HEU compared with HIV-unexposed children in sub-
Saharan Africa [5,19,30,35,36]. Increased risk of diar-
rhea-related morbidity in HEU might be a consequence
of suboptimal breastfeeding rather than of HIV exposure
itself. In contrast, as in the previous study performed in
the same setting, the incidence of outpatient attendances
was higher in HIV-unexposed children compared with
HEU. This might be explained by the antibacterial effect
of the routinely administered CTXp to HEU children
from 6 weeks of age [19]. The special clinical follow-up of
HEU children at the HRPOC might have also reduced
outpatient healthcare utilization by HEU children.
HEU children were more likely to have higher incidence
of both malnutrition-related hospital admissions and
overall moderate and severe malnutrition during the first
18 months of life compared with HIV-unexposed
children. HIV exposure during pregnancy has been
associated with poor pregnancy outcomes such as preterm
birth or LBW compared with nonexposed children
[19,37–40]. In this study, prevalence of preterm birth was
higher in HEU children compared with HIV-unexposed
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Table 5. Risk factors for hospital admissions in HIV-exposed uninfected infants.
Variable n Categories









Sex 684 Male 1 0.6541 1 0.8055
Female 0.90 (0.58, 1.41) 0.93 (0.51, 1.70)
Age 909 0 to <1 month 1 0.0254 1 0.0517
1 to <6 months 0.39 (0.17, 0.85) 0.37 (0.09, 1.52)
6 to <12 months 0.34 (0.16, 0.72) 0.24 (0.01, 1.05)
12 to <18 months 0.33 (0.15, 0.70) 0.13 (0.03, 0.64)
Birth weight 494 2500 1 (0.40, 2.26) 0.9033 1 0.5567
<2500 0.95 0.68 (0.19, 2.42)
Type of delivery 495 Vaginal 1 0.9695 1 0.5521
Cesarean 0.98 (0.35, 2.77) 1.39 (0.47, 4.16)
Location of delivery 497 Maternity 1 0.6799 1 0.8717
Home 0.60 (0.18, 1.95) 0.66 (0.14, 3.11)
Other 1.22 (0.15, 9.54) 0.00 –
Gestational age (weeks) 384 37 weeks 1 0.9279 1 0.5864
<37 weeks 1.03 (0.53, 2.01) 1.24 (0.57, 2.69)
Mother on CTXpb 474 No 1 0.5228 1 0.6979
Yes 0.85 (0.52, 1.40) 0.89 (0.48, 1.64)
Breastfeeding 684 Exclusive 1 0.3682 1 0.0177
Partial 0.95 (0.45, 2.04) 2.21 (0.70, 6.99)
Weaned 1.48 (0.63, 3.46) 6.74 (1.87, 24.31)
Never did 1.48 (0.68, 3.20) 2.63 (0.92, 7.52)
Maternal ARTc 684 No 1 0.6262 1 0.5378
Yes 0.81 (0.35, 1.87) 1.37 (0.51, 3.70)
Child PMTCTd 684 No 1 0.9461 1 0.5552
Yes 0.98 (0.62, 1.57) 0.77 (0.31, 1.86)
Child CTXpb 684 No 1 0.0242 1 0.9356




dPrevention of mother-to-child transmission of HIV.children, though data on gestational age at the time of
delivery were only available in one-third of the HEU
infants. However, the role of HIV exposure during
pregnancy, delivery and breastfeeding on postnatal
growth remains uncertain. Previous to availability of
antiretroviral drugs, several studies showed poor growth
outcomes in HEU children compared with HIV-
unexposed children [41,42]. However, reports in which
antiretroviral drugs for PMTCT were used either found
no differences in growth outcomes between HEU and
HIV-unexposed children or if they existed were most
likely due to different feeding practices rather than to
HIV exposure [43,44].
The incidence of outpatient attendances in HEU children
increased with age. Although exclusive breastfeeding is
considered sufficient to provide adequate nutrition and
immunological protection to infants during the first 6
months, the likely inadequacy, both in quantity and
nutritional quality of weaning foods, together with
exposure to infectious diseases may compromise the
infant’s health onward [45–48]. Another risk factor for
outpatient attendance among HEU children was having a
mother on ART during pregnancy. At the time of the
study, women had to meet immunological and clinical
criteria to start HIV treatment, being those moreinmunosuppressed or with advanced clinical stage the
ones who were eligible for ART. Offspring born to
women with advanced HIV infection and eventually at
higher risk of maternal mortality during childhood might
be particularly vulnerable. In addition to an adverse social
and economic background, compared with healthy
mothers, those who are immunodeficient or clinically
unwell might be less able to provide appropriate child
care, adequate duration of breastfeeding or more likely to
carry infectious pathogens harmful to their infants
[49,50].
The main limitation of this study is the difference in the
follow-up between both cohorts. The HEU cohort was
followed up by passive surveillance at the HRPOC, and
the HIV-unexposed cohort included children participat-
ing in a clinical trial who were actively followed up from
birth. Another limitation is that information on feeding
practices was not available for HIV-unexposed children
limiting the availability to infer their effect on the the
differences between HEU and HIV-unexposed children.
On the other hand, undetected HIV infections occurring
in between the recommended HIV testings in HEU
children might have influenced the results, as HIV-
infected children tend to have worst health outcomes
compared with HEU children [51]. Information on HEU
CE: Swati; AIDS-D-16-01137; Total nos of Pages: 9;
AIDS-D-16-01137
8 AIDS 2017, Vol 00 No 00children was obtained from passive surveillance at the
HRPOC, and consequently there were missing data for
some of the independent variables, which may limit the
interpretation of the multivariate analysis.
In conclusion, increased morbidity and mortality was
observed in HEU children compared with HIV-
unexposed children. New programs and interventions
must take into consideration the long-term health needs
of this growing population; they should also address
transmission from mother to child, not only in terms of
infant infections avoided, but also in terms of child
survival. Due to the scale-up of option Bþ, MTCT of
HIV is reducing and therefore the number of HIV-
infected children. However, the prevalence of HIV-
infected mothers is maintained, and thus the number of
HEU children who have specific health needs that should
be focused on to ensure that post-2015 sustainable
development goals are achieved.Acknowledgements
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